title: ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis.
abstract: BACKGROUND
  A number of researches have evaluated the association between the ABCB1 polymorphism and the lipid-lowering response of statins, but the results have been inconclusive. To examine the lipid-lowering efficacy and safety associated with the ABCB1 C3435T polymorphism in hypercholesterolemic patients receiving statin, all available studies were included in this meta-analysis.
  
  
  METHODS
  A systematic search for eligible studies in the Cochrane library database, Scopus and PubMed was performed. Articles meeting the inclusion criteria were comprehensively reviewed, and the available data were accumulated by the meta-analysis.
  
  
  RESULTS
  The results indicated that the comparisons of CC+CT vs. TT were associated with a significant elevation of the serum HDL-C levels after statin treatment (CC+CT vs. TT: MD, 2.46; 95 % CI, 0.36 to 4.55; P = 0.02), and the ABCB1 C3435T variant in homozygotes was correlated with decreases in LDL-C (CC vs. TT: MD, 2.29; 95 % CI, 0.37 to 4.20; P = 0.02) as well as TC (CC vs. TT: MD, 3.05; 95 % CI, 0.58 to 5.53; P = 0.02) in patients treated with statin. However, we did not observe a significant association in the TG group or an association between other genetic models serum lipid parameters. In addition, statin treatment more than 5 months led to a higher risk of muscle toxicity.
  
  
  CONCLUSIONS
  The evidence from the meta-analysis demonstrated that the ABCB1 C3435T polymorphism may represent a pharmacogenomic biomarker for predicting treatment outcomes in patients on statins and that statin treatment for more than 5 months can increase the risk of myopathy.
authors.affiliation: Department of Gerontology, Ningbo No.1 Hospital, Ningbo, Zhejiang Province, 315010, People's Republic of China. nbsj54@126.com.
authors.forename: Jia
authors.initials: J
authors.lastname: Su
authors.affiliation: Department of Gerontology, Ningbo No.1 Hospital, Ningbo, Zhejiang Province, 315010, People's Republic of China. jjxh425@163.com.
authors.forename: Hongyu
authors.initials: H
authors.lastname: Xu
authors.affiliation: Department of Gerontology, Ningbo No.1 Hospital, Ningbo, Zhejiang Province, 315010, People's Republic of China. yangjun4499@163.com.
authors.forename: Jun
authors.initials: J
authors.lastname: Yang
authors.affiliation: Department of Traditional Chinese Internal Medicine, Ningbo No.1 Hospital, Ningbo, Zhejiang Province, People's Republic of China. yuqinglin1@163.com.
authors.forename: Qinglin
authors.initials: Q
authors.lastname: Yu
authors.affiliation: Department of Hematology, Ningbo No.1 Hospital, Ningbo, Zhejiang Province, People's Republic of China. yashjun@126.com.
authors.forename: Shujun
authors.initials: S
authors.lastname: Yang
authors.affiliation: Department of Gerontology, Ningbo No.1 Hospital, Ningbo, Zhejiang Province, 315010, People's Republic of China. 2559309191@qq.com.
authors.forename: Jianjiang
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Department of Gerontology, Ningbo No.1 Hospital, Ningbo, Zhejiang Province, 315010, People's Republic of China. nbyaoqi@sina.com.
authors.forename: Qi
authors.initials: Q
authors.lastname: Yao
authors.affiliation: Department of Gerontology, Ningbo No.1 Hospital, Ningbo, Zhejiang Province, 315010, People's Republic of China. zhuyunyun0122@sina.com.
authors.forename: Yunyun
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: Department of Gerontology, Ningbo No.1 Hospital, Ningbo, Zhejiang Province, 315010, People's Republic of China. xlxx1983@126.com.
authors.forename: Yuan
authors.initials: Y
authors.lastname: Luo
authors.affiliation: Department of Biochemistry, School of Medicine, Ningbo University, Ningbo, Zhejiang Province, People's Republic of China. jilindan@nbu.edu.cn.
authors.forename: Lindan
authors.initials: L
authors.lastname: Ji
authors.affiliation: Department of Gerontology, Ningbo No.1 Hospital, Ningbo, Zhejiang Province, 315010, People's Republic of China. 1105267668@qq.com.
authors.forename: Yibo
authors.initials: Y
authors.lastname: Zheng
authors.affiliation: Department of Gerontology, Ningbo No.1 Hospital, Ningbo, Zhejiang Province, 315010, People's Republic of China. nbyujingbo@163.com.
authors.forename: Jingbo
authors.initials: J
authors.lastname: Yu
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B / Q000097:blood / Q000235:genetics; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D015870:Gene Expression; D006720:Homozygote; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D006937:Hypercholesterolemia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000097:blood / Q000139:chemically induced / Q000235:genetics / Q000473:pathology; D020641:Polymorphism, Single Nucleotide; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
chemical_list: C513055:ABCB1 protein, human; D018435:ATP Binding Cassette Transporter, Subfamily B; D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014280:Triglycerides